A Study to Assess Use of Zenapax (Daclizumab) and CellCept (Mycophenolate Mofetil) to Improve Kidney Function in Kidney Transplant Patients

• Status: Completed
• Trial end date: 2006-03-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will compare kidney function in kidney transplant patients following treatment with various combinations of Zenapax, CellCept, corticosteroids, and Neoral (Cyclosporine). The anticipated time on study treatment is 6-12 months, and the target sample size is 500+ individuals.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hoffmann-La Roche
• Treatments: Cyclosporine; Cyclosporins; Daclizumab; Mycophenolate mofetil; Mycophenolic Acid

Criteria

Inclusion Criteria:

• adult patients greater than 18 years of age

• recipients of primary kidney transplant

• single-organ recipients (kidney only)

Exclusion Criteria:

• previous treatment with Zenapax

• history of malignancy (except localized skin cancer)